Compare APEI & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APEI | EBS |
|---|---|---|
| Founded | 1991 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 653.8M | 595.6M |
| IPO Year | 2007 | 2006 |
| Metric | APEI | EBS |
|---|---|---|
| Price | $43.50 | $11.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $42.43 | $15.00 |
| AVG Volume (30 Days) | 204.2K | ★ 942.5K |
| Earning Date | 03-05-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 133.01 | N/A |
| EPS | 1.30 | ★ 1.35 |
| Revenue | $654,642,000.00 | ★ $788,900,000.00 |
| Revenue This Year | $4.89 | N/A |
| Revenue Next Year | $6.76 | $15.21 |
| P/E Ratio | $32.03 | ★ $8.54 |
| Revenue Growth | ★ 6.75 | N/A |
| 52 Week Low | $18.77 | $4.02 |
| 52 Week High | $44.88 | $14.06 |
| Indicator | APEI | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 64.03 | 46.63 |
| Support Level | $40.80 | $11.28 |
| Resistance Level | $44.88 | $11.96 |
| Average True Range (ATR) | 1.79 | 0.68 |
| MACD | -0.06 | -0.06 |
| Stochastic Oscillator | 76.50 | 49.75 |
American Public Education Inc provides online and campus based postsecondary education including various undergraduate and graduate degree programs. The fields of study include business administration, health science, technology, criminal justice, education, liberal arts, national security, military studies, intelligence, and homeland security. There are three reporting segments: the American Public University segment which is the key revenue generator; the Rasmussen University Segment and the Hondros College of Nursing segment. The revenue is generated from net course registrations and enrollment, tuition rate, net tuition, and other fees.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.